Close Menu

NEW YORK – Axim Biotechnologies plans to use an assay developed by recently acquired Sapphire Biotech as a companion diagnostic for drugs in development that inhibit  quiescin sulfydryl oxidase 1 (QSOX1), a tumor-derived enzyme involved in metastasis. 

Initially, San Diego-based Axim expects to launch it as a tissue-based, immunohistochemistry test in mid-2021. By early 2022, the company, which is also developing analogs to a drug it has licensed from Arizona State University, expects to market a dipstick version of the assay using plasma samples.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.